Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis

BACKGROUND: Sustaining clinical remission is an important treatment goal in moderate-to-severe UC. This post hoc exploratory analysis assessed the long-term efficacy of vedolizumab in the subset of patients with UC in the GEMINI 1 study who were in clinical remission by week 14 after 3 induction dos...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Inflamm Bowel Dis
Auteurs principaux: Feagan, Brian G, Schreiber, Stefan, Wolf, Douglas C, Axler, Jeffrey L, Kaviya, Arpeat, James, Alexandra, Curtis, Rebecca I, Geransar, Parnia, Stallmach, Andreas, Ehehalt, Robert, Bokemeyer, Bernd, Khalid, Javaria Mona, O’Byrne, Sharon
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2019
Sujets:
Original Clinical Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6499937/
https://ncbi.nlm.nih.gov/pubmed/30365009
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ibd/izy323
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires